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Head-to-HeadComparison of FamilyHistory of Colorectal
Cancer and a Genetic Risk Score for Colorectal Cancer
Risk Stratification
Korbinian Weigl, PhD1,2,3, Li Hsu, PhD4, Phillip Knebel, MD5, Michael Hoffmeister, PhD1, Maria Timofeeva, PhD6, Susan Farrington, PhD6,
Malcolm Dunlop, MD6 and Hermann Brenner, MD1,2,7
OBJECTIVES: Family history (FH) is associated with increased risk of colorectal cancer (CRC). We aimed to examine
the potential for CRC risk stratification by known common genetic variants beyond FH in a large
population-based case-control study from Germany.
METHODS: Four thousand four hundred forty-seven cases and 3,480 controls recruited in 2003–2016 were
included for whom comprehensive interview, medical, and genomic data were available. Associations
with CRC risk were estimated from multiple logistic regression models for FH and a genetic risk score
(GRS) based on 90 previously identified risk variants.
RESULTS: CRC in a first-degree relative was associated with a 1.71-fold (95% confidence interval 1.47–2.00)
increase in CRC risk. A higher risk increase (odds ratio 2.06, 95% confidence interval 1.78–2.39) was
estimated for the GRS when it was dichotomized at a cutoff yielding the same positivity rate as FH
among controls. Furthermore, the GRS provides substantial additional risk stratification in both people
with andespeciallywithout FH.Equal or even slightly higher riskswere observed for participants without
FH with a GRS in the upper 20% compared with participants with FH with a GRS below median. The
observed patterns were confirmed in a replication study.
DISCUSSION: In contrast to common perception, known genetic variants do not primarily reflect some minor share of
the familial excess risk of CRC, but rather reflect a substantial share of risk independent of FH.
SUPPLEMENTARY MATERIAL accompanies this article at http://links.lww.com/CTG/A134
Clinical and Translational Gastroenterology 2019;10:e00106. https://doi.org/10.14309/ctg.0000000000000106
INTRODUCTION
With an estimated toll of 1.8million new cases and 881.000 deaths
in 2018, colorectal cancer (CRC) is the third most common
cancer and the second most common cancer cause of death
globally (1). It has long been noted that first-degree relatives
(FDRs) of patients with CRC have a strongly increased risk of
CRC (2), and guidelines for CRC screening consistently recom-
mend to start CRC screening at a younger age in this high-risk
population than in the average-risk population (3).
The excess risk among relatives of patients with CRC is gen-
erally assumed to be explained to a large extent by shared genetic
risk variants (4). A large number of genetic risk variants for CRC
have been identified by genomewide association studies
(GWASs) (e.g., (5–10)). Although the risk associated with each of
the identified common single nucleotide polymorphisms (SNPs)
is generally very small, construction of genetic risk scores (GRSs)
based on absolute or weighted numbers of risk alleles from
multiple SNPs has been shown to be a promising avenue for
effective risk stratification in CRC screening (11–13).
Although we were already able to confirm these previous
results and additionally show that combination of both family
history (FH) and common genetic variants enhances CRC risk
stratification (14), the question about the potential of these var-
iants in direct comparison with FH remains unanswered. Simi-
larly, the magnitude to which risk stratification by common
genetic variants in both people with andwithout FH (the only risk
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stratification criterion commonly used in various CRC guide-
lines) could be used has not yet been addressed. In this article, we
aimed for evaluating the potential for CRC risk stratification by
common genetic risk variants identified by GWAS beyond the
commonly used risk stratification by FH.
METHODS
Study design and study population
Data for the analyses were drawn from the DACHS study
(Darmkrebs: Chancen der Verhütung durch Screening) which has
been described in detail elsewhere (15,16). In brief, DACHS is an
ongoing population-based case-control study in the Rhine-Neckar
region in southwest Germany. German-speaking patients aged 30
years or older with a first diagnosis of CRC who are capable of
taking part in a personal interview of approximately 1 hour are
eligible for participation. Physicians inform patients with a first
diagnosis ofCRCabout the study.Approximately 50%of all eligible
patients in the study area are recruited. Using frequency matching
with respect to sex, age, and county of residence, controls are
randomly selected from population registries. Besides excluding
persons with a history of CRC among controls, inclusion and ex-
clusion criteria are identical for both cases and controls. This
analysis is based on 4,447 cases and 3,480 controls who were
recruited from 2003 to 2016 and for whom data fromGWASwere
available. The participation rate among controls was 51%. The
ethics committees of the Medical Faculty at the University of
Heidelberg (310/2001) and the Medical Chambers of Baden-
Württemberg and Rhineland-Palatinate approved the study.
Written informed consent was obtained from all participants.
Data collection
The study center was informed about cases after they had given
written informed consent. Controls were contacted by mail and
follow-up telephone calls. Standardized in-person interviews
were conducted with both cases (typically during their hospital
stay) and controls (at their homes) by trained interviewers. In
these interviews, blood or buccal samples were collected, and
a broad variety of risk factors and preventive factors for CRCwere
addressed in great detail. In particular, detailed information about
the participants’ FH was collected (degree of kinship, number of
affected relatives, and age at diagnosis). All cases with primary
CRC were histologically confirmed.
Genotyping
DNAwas extracted fromblood samples (in 99.1%of participants)
or from buccal cells (in 0.9% of participants) using conventional
methods. Details about genotyping and imputation of missing
genotypes are provided in Table 1 of the Supplementary Digital
Content 1 (http://links.lww.com/CTG/A134).
Identification and selection of SNPs for the GRS
We considered a most recently reported set of 95 SNPs that were
identified to be associated with a higher risk of CRC in the world’s
largest CRC GWAS in populations of European descent (17). Of
the reported 95 SNPs, a total of 90 SNPs could be extracted from
our data set (see Table 2 of Supplementary Digital Content 1,
http://links.lww.com/CTG/A134). The GRS was calculated as the
sum of risk alleles (as reported by Huyghe et al. (17)).
Statistical analysis
We first described the study population according to the distri-
bution of sex, age, FH of CRC, and the GRS. We compared the
distribution of the GRS between cases and controls and between
participants with and without FH (latter both among cases and
among controls). Differences between groups were tested for
statistical significance by the Mann-Whitney U test.
We then assessed the associations of FH with CRC risk using
multiple logistic regression models and adjusting for covariates
that are known or suspected to be associated with CRC risk (see
Table 2 for description). Associations were quantified by adjusted
odds ratios (ORs) and their 95% confidence intervals (CIs).
For comparison reasons, we then performed analogous anal-
yses for the GRS, for which we dichotomized participants
according to whether or not their GRS exceeded a defined cutoff
(selected in such a way that the proportions of participants in the
control group exceeding the cutoff equaled the corresponding
proportions meeting the respective FH criteria).
We then examined the joint association of the GRS and FH
with the risk of CRC. For this purpose, we divided participants
with a positive FH in FDR into 2 groups (equal to or smaller vs
greater than median number of risk alleles in controls with FH, n
5 86). To allow for meaningful comparisons especially in the
high-risk and low-risk group, we then categorized persons
without FH into 7GRS groups with cutoffs at the 10th, 20th, 40th,
60th, 80th, and 90th percentile of the risk alleles among controls
without FH. Compared with the reference group of participants
without FH and GRS in the bottom decile, we estimated the CRC
risk of all other groups. Additional analyses were conducted
which examined the association of GRS with CRC risk according
to participants’ history of colonoscopy.
All statistical analyses were conducted using SAS software,
version 9.4 (SAS Institute, Cary, NC) and R statistical software
package (18). Two-sided P values less than 0.05 were considered
statistically significant.
Replication analyses
Main analyses were replicated using the Study of Colorectal Cancer
in Scotland (SOCCS), a population-based case-control study con-
ducted between 1996 and 2006. Details of study recruitment and
data collection have been previously described in detail (19). The
study included1,556 incidentCRCcases, and2,201adult cancer-free
controls, identified from the Community Health Index in Scotland.
Genotyping was conducted using custom Illumina Infinium arrays
and OmniExpressExome BeadChip arrays. Detailed descriptions of
genotyping and imputation of common genetic variants are pre-
sented in previous reports (20,21). The study was approved by the
Multicenter Research Ethics Committee for Scotland (reference
number: 01/0/05) and by the Research and Development Office of
NHS Lothian (reference number: 2003/W/GEN/05).
RESULTS
Of 5,067 cases and 5,271 controls who were recruited in DACHS
until 2016, a total of 4,447 cases and 3,480 controls have been
genotyped, fulfilled quality control criteria, and had complete data
on FH. We excluded 5 cases who fulfilled the Amsterdam criteria
and who were potential carriers of the Lynch syndrome (Figure 1).
Table 1 shows some main characteristics of the study pop-
ulation. Approximately 60% of both cases and controls were men.
The agedistributionwas similar among cases and controls (median
age: cases 69 years and controls 70 years), as expected as a result of






matching. One of 10 controls (10.0%) had an FDR with CRC, and
apositive FHwasmore commonamongcases than among controls
according to all FH definitions. The median GRS was 87 among
cases and 85 among controls (P, 0.0001) (Table 1, see Figure 1 of
Supplementary Digital Content 1, http://links.lww.com/CTG/
A134). Substantially smaller but still statistically significant dif-
ferences were seen between those with and those without an FH of
CRC in any FDR, both within controls and within cases (see Fig-
ure 1 of Supplementary Digital Content 1, http://links.lww.com/
CTG/A134).
Table 2 shows the ORs for the associations between FH and
GRS and CRC risk. ORs for FH in DACHS were 1.64 (95% CI
1.44–1.86) for any first- or second-degree relative with CRC
and 1.71 (95% CI 1.47–2.00) for having an FDR. Higher ORs
were estimated for the GRS when it was dichotomized at levels
yielding the same proportions of affected controls as the 2 FH
definitions (ORs 2.12, 95% CI 1.88–2.39 and 2.06, 95% CI
1.78–2.39, respectively).
A comparison of the potential of CRC risk stratification with
either information about FH in an FDR or the GRS is shown in
Figure 2. Information obtained from the binary FH status yielded
increased risk of the small proportion of persons with an affected
relative compared to persons without an affected relative
(Figure 2a). Dichotomizing the GRS so that the prevalence of
exposed participants equals the prevalence of an FH in an FDR
resulted in a very similar outcome,withhigher odds for the exposed
group (Figure 2b). However, much information that can be used
for enhanced and refined risk stratification is lost in the di-
chotomized GRS compared with the continuous GRS (Figure 2c,
hatched area).
Table 3 shows the joint association of FH and the GRS with
the risk of CRC. Compared with the reference group of persons
without FH and the lowest genetic risk (bottomdecile of number
of risk alleles among controls without FH), people with an FH
have a strongly increased risk of CRC (OR 4.65, 95% CI
3.51–6.14 and OR 2.76, 95% CI 2.06–3.69 for people with higher
genetic risk and for people with lower genetic risk, respectively).
Among those with no FH, the CRC risk steadily increases with
increasing GRS up to ORs for people in the top 2 GRS groups of
3.88 (95% CI 3.03–4.96) and 3.16 (95% CI 2.46–4.06), i.e., to
ORs comparable with those of the half of people with FH with
lower GRS.
Sensitivity analyses stratifying by cancer stage (see Table 2 of
Supplementary Digital Content 1, http://links.lww.com/CTG/
A134) showed similar results for each cancer stage, with slightly
higher risk estimates for stage 4.
Stratified analyses by age of participant confirmed the overall
pattern for all age groups, but revealed an especially pronounced
Table 1. Characteristics of the study population
Characteristic
Cases Controls
P valueN % N %
Sex
Men 2,698 60.7 2,136 61.4 0.5206
Women 1,749 39.3 1,344 38.6
Age
,50 220 5.0 146 4.2 0.0208
50–64 1,275 28.7 970 27.9
65–74 1,571 35.3 1,339 38.5
751 1,381 31.1 1,025 29.5
FH
No FH (in any first- or second-degree
relative)
3,487 78.4 2,896 83.2 ,0.0001
Any first- or second-degree relative 960 21.6 584 16.8
Any first-degree relative 608 13.7 348 10.0 ,0.0001
GRS
Median 87 85 ,0.0001
Interquartile range 83–90 81–88
Range 60–109 64–102
Cancer stagea
1 1,029 23.1 — —
2 1,337 30.1 —
3 1,417 31.9 —
4 644 14.5 —
FH, family history; GRS 5 genetic risk score.
aCancer stage missing for 20 cases.
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CRC risk increase for younger participants (see Table 4 of Sup-
plementary Digital Content 1, http://links.lww.com/CTG/A134).
Replication analyses of the main results in SOCCS are pre-
sented in Tables 6–8 and in the Figures 2 and 3 of the Supple-
mentary Digital Content 1 (http://links.lww.com/CTG/A134).
Overall, the population in the SOCCS was younger compared
withDACHS participants, andmore cases had an FH in an FDR
(17.1% vs 13.7% in DACHS, Appendix Table 6, http://links.
lww.com/CTG/A134). Because data on second-degree relatives
were not available in SOCCS, replication analyses focused
on FDR. A higher OR for CRC associated with having an FH in
an FDR was obtained in SOCCS compared with DACHS (2.19,
95% CI 1.79–2.70), but dichotomizing the GRS to generate
the same proportion of exposure yielded a comparable OR
compared with FH (2.07, 95% CI 1.69–2.53). Overall, the joint
association of GRS and FH with CRC risk in SOCCS yielded
similar results as analyses in DACHS. Figure 2 of the Supple-
mentary Digital Content (http://links.lww.com/CTG/A134)
confirms the patterns observed in DACHS, with major differ-
ences in the GRS distribution between cases and controls, but
not at all or not as distinct between persons with and without
FH in either cases or controls, respectively. The replication of
the enhanced risk stratification by a continuous GRS compared
with binary variables such as FH is depicted in Figure 3 of the
Supplementary Digital Content 1 (http://links.lww.com/CTG/
A134).
DISCUSSION
In this large case-control study, we aimed for an evaluation of the
associations of FH and a GRS based on common genetic variants
with the risk of CRC. Althoughmost FH definitions are restricted
to 2 groups (those with and those without FH), a GRS provides
information over the complete spectrum of its range. Taking this
information into account, the GRS adds valuable information
with respect to risk stratification especially in personswithout FH,
some proportion of whom have as high or even higher risk than
those with a positive FH. We could replicate our findings in an
independent cohort.
Our analyses showed that 20% of persons without FH (10%
in the replication cohort, respectively) have at least a compa-
rable CRC risk because of their increased genetic risk compared
with 50% of persons with an FH in an FDR (i.e., those with FH,
but GRS below the median). Considering that persons without
FH are constituting 90% of the population, 20% of this group is
a larger share of the total population (approximately 18%) than
half the population with an FH (approximately 5%), for whom
CRC risk is deemed to be increased in a way that earlier
screening initiation is recommended. Arguably, comparable
CRC risk should yield comparable CRC screening guidelines.
Potential implications for risk stratification could be as follows:
while people with an FH of CRC should be advised to start
screening earlier as commonly recommended, people without
FH might be offered determination of a GRS for risk stratifi-
cation, in that those above the 80th percentile might be advised
to start screening earlier, similar to those with an FH, and those
with lower GRS might be advised to follow recommendations
Figure 1. Flow diagram of study participants. FH, family history; GWAS,
genomewide association study; QC, quality control.




OR (95% CI)an % n %
FH First- or second-degree relative 960 21.6 584 16.8 1.64 (1.44–1.86)
First-degree relative 608 13.7 348 10.0 1.71 (1.47–2.00)
GRSb Upper 16.8% 1,304 29.3 591 17.0 2.12 (1.88–2.39)
Upper 10.0% 798 17.9 350 10.1 2.06 (1.78–2.39)
CI, confidence interval; CRC, colorectal cancer; DACHS,Darmkrebs, Chancen der Verhütung durch Screening; FH5 Family history; GRS5 genetic risk score; OR, odds ratio.
aAdjusted for sex (female/male), age (yr, continuous), education (#9, 10–11, $12 yr), previous colonoscopy (yes/no), smoking (current/former/never), hormone
replacement therapy amongwomen (yes/no), andbodymass index before diagnosis (weight in kgdividedby squared height inmeters); reference category: participants not
meeting the respective FH definition or people with a GRS below the cutoff respectively; missing values, n 5 140.
bGRS dichotomized in such a way that the positivity rate in controls equals the prevalence of either FH definition (cutoff for upper 16.8% and 10.0%, 90 risk alleles and 92
risk alleles, respectively).






for the average risk population. It remains to be clarified how
risk stratification with a GRS could be practically implemented
in existing health care models, especially given the sensitive
nature of genetic testing. One possibility could be to merely
communicate a quantitative measure (e.g., solely the sum of
risk alleles) and the associated CRC risk, which may be trans-
lated in a personalized recommendation for the starting age of
CRC screening, to avoid unnecessary concern about the indi-
viduals’ genetic condition. Approaches like these should how-
ever be indeed evaluated, especially considering that the
positive FH criterion could become less important in future risk
stratification approaches if persons meeting screening recom-
mendations actually participate in CRC screening (22). Fewer
people would then exhibit an FH of CRC leaving behind many
persons without FH for whom no risk-adapted screening rec-
ommendations are yet established.
The observed associations also show that it is misleading to
think of genetic risk only in the context of a positive FH. Instead,
as illustrated by our results, the GRS not just explains a small
proportion of the excess risk associated with FH. Rather, it is
responsible for a large proportion of the high end CRC risk in
the population in general. Moreover, whereas FH only conveys
risk information at the upper end for a small high-risk pro-
portion, the GRS provides information beyond dichotomization
and offers risk stratification potential over the full range of its
distribution in the population, most importantly also in persons
without FH. The GRS can hence not only be used to identify
people at highest risk in whom initiating screening at younger
ages or in shorter intervals might be warranted but also it pro-
vides the opportunity to help identifying low-risk individuals
for whom CRC screening could start at a later age or be less
intensive.
Our study has a number of specific strengths and limitations.
Strengths include the large sample size and unselected
population-based multicenter recruitment of cases and controls
in a defined large area. Furthermore, in contrast to most other
studies, no upper age limit was used. Because many CRC cases
occur at relatively old ages (mean ages at diagnosis are 75 years
for women and 69 years for men), our results should provide
a more comprehensive estimation of ORs than studies from
selective academic centers or population subgroups. The anal-
yses were furthermore replicated in an independent cohort from
Scotland.
On the other hand, we cannot rule out some selection bias in
DACHS by recruitment of approximately 50% of eligible cases
and controls only.Main reasons for nonrecruitment of cases were
overload of their treating physicians (through whom recruitment
had to be realized) or patients being too sick to be able to par-
ticipate, and the latter was also amajor reason of nonparticipation
of controls, especially at older ages. There seems to be no obvious
Figure 2. CRC risk associated with FH in FDR and GRS and affected proportions of population. (a) CRC risk and affected proportion of FH in FDR. (b) CRC
risk and affectedproportion of dichotomizedGRS. (c) CRC risk and affectedproportion of dichotomized and continuousGRS. CRC, colorectal cancer; FDR,
first-degree relative; FH, family history; GRS, genetic risk score; OR, odd ratio.
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reason, however, to assume that these factors were related to FH
or the GRS, the main variables of interest in our analysis. In-
formation on FH was self-reported and may be subject to lack of
awareness and imperfect recall and reporting. In particular, cases
may bemore aware of a positive FHwhichmight have led to some
overestimation of the associations of FHwithCRC risk. However,
previous studies have shown self-reported CRC in an FDR to be
rather accurate (23,24), with little variation between cases and
controls (23,25), suggesting that the potential bias is likely to be
limited (23–25). Although the observed associations of SNPs
often reflect indirect effects, which diminish the use of SNPs and
the resulting GRS for causal inferences, it does not necessarily
limit the use of GRS for risk prediction and risk stratification.We
used unweighted GRS for this analysis (i.e., number of risk
alleles), but previous research suggests that weighted GRS
(i.e., weighting SNPs with respective log[OR]) yields comparable
results (12,26). Although our study sample was large, sample size
issues limited more refined GRS groups, especially in the FH
positive population. Our results pertain to a study population of
almost exclusively white origin. Although GRS for other eth-
nicities is likely to differ with respect to the variants included (e.g.,
(27)), it seems unlikely that the observed patterns of comple-
mentary risk information by FH and GRS should be substantially
different in other ethnic groups.
The presented results confirm previous analyses conducted in
a subset of this study population (14) in that CRC risk stratifi-
cation might strongly benefit from including information about
GRS together with FH. Given the larger sample size, we were able
to examine in more detail the direct comparison between GRS
and FH, which was not possible in the previous analysis.
In conclusion, our study demonstrates the complementary
character of an FH of CRC and meanwhile identified common
genetic variants on CRC risk. These genetic variants do not pri-
marily reflect some minor share of the familial excess risk, but
rather reflect most relevant risk information independent of the
risk that has previously becomemanifest in the family. GRSmight
therefore be useful supplements to existingCRC risk scores or risk
stratification criteria far beyond FH which is already included in
most of them.
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Table 3. Joint association between GRS, FH in a first-degree
relative, and CRC risk
FH GRS percentilea Cases, n Controls, n OR (95% CI)b
Positive .50 370 174 4.65 (3.51–6.14)
#50 238 174 2.76 (2.06–3.69)
Negative .90 673 313 3.88 (3.03–4.96)
.80–90 547 298 3.16 (2.46–4.06)
.60–80 788 583 2.36 (1.88–2.97)
.40–60 796 678 2.08 (1.66–2.61)
.20–40 623 633 1.75 (1.39–2.21)
.10–20 230 314 1.21 (0.92–1.58)
#10 182 313 1.00 (Ref.)
CI, confidence interval; CRC, colorectal cancer; FH, family history; GRS, genetic
risk score; OR, odds ratio.
aPercentiles of GRS calculated in controls in respective FH group.
bModel adjusted for sex, age, education, previous colonoscopy, smoking,
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3 Having an FH of CRC increases the risk of CRC and is
therefore used as a risk stratification criterion in pertinent
guidelines.
3 Many common genetic variants have been found to increase
the risk of CRC.
WHAT IS NEW HERE
3 Known genetic variants do not primarily reflect some minor
share of the familial excess risk of CRC, but rather reflect
a substantial share of risk independent of FH.
3 Using both information on common genetic variants and
a self-reported FH substantially enhances risk stratification,
especially for individuals without FH, for whom no risk-
adapted prevention strategies are currently available.
TRANSLATIONAL IMPACT
3 Genetic risk scores could help to identify high risk individuals
for whom no risk-adapted screening strategies are yet
developedbutwho carry similar risks to people forwhomsuch
strategies are commonly used.
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